- Home
- PHH vs NLSP Comparison
PHH vs NLSP Comparison
Compare PHH & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHH
- NLSP
- Stock Information
- Founded
- PHH 2016
- NLSP 2015
- Country
- PHH China
- NLSP Switzerland
- Employees
- PHH N/A
- NLSP N/A
- Industry
- PHH Package Goods/Cosmetics
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PHH Consumer Discretionary
- NLSP Health Care
- Exchange
- PHH Nasdaq
- NLSP Nasdaq
- Market Cap
- PHH 12.3M
- NLSP 12.4M
- IPO Year
- PHH 2024
- NLSP 2021
- Fundamental
- Price
- PHH $0.45
- NLSP $2.17
- Analyst Decision
- PHH
- NLSP
- Analyst Count
- PHH 0
- NLSP 0
- Target Price
- PHH N/A
- NLSP N/A
- AVG Volume (30 Days)
- PHH 990.2K
- NLSP 193.8K
- Earning Date
- PHH 01-01-0001
- NLSP 10-17-2025
- Dividend Yield
- PHH N/A
- NLSP N/A
- EPS Growth
- PHH N/A
- NLSP N/A
- EPS
- PHH N/A
- NLSP N/A
- Revenue
- PHH $2,768,120.00
- NLSP N/A
- Revenue This Year
- PHH N/A
- NLSP N/A
- Revenue Next Year
- PHH N/A
- NLSP N/A
- P/E Ratio
- PHH N/A
- NLSP N/A
- Revenue Growth
- PHH 42.65
- NLSP N/A
- 52 Week Low
- PHH $0.41
- NLSP $1.30
- 52 Week High
- PHH $41.49
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- PHH 29.13
- NLSP 49.77
- Support Level
- PHH $0.44
- NLSP $1.88
- Resistance Level
- PHH $0.56
- NLSP $2.02
- Average True Range (ATR)
- PHH 0.06
- NLSP 0.13
- MACD
- PHH 0.28
- NLSP -0.01
- Stochastic Oscillator
- PHH 18.23
- NLSP 55.77
About PHH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.